Difficulty: Medium
Average Score: 87%
Testbank
A patient has developed hepatic encephalopathy secondary to cirrhosis and is receiving care on the medical unit. The patients current medication regimen includes lactulose (Cephulac) four times daily. What desired outcome should the nurse relate to this pharmacologic intervention?
Correct answer
A
Rationale
A: Two to 3 soft bowel movements daily.
Lactulose is a non-absorbable disaccharide that helps reduce ammonia levels by promoting the excretion of ammonia through the stool. The desired outcome of administering lactulose in a patient with hepatic encephalopathy is to achieve two to three soft bowel movements daily, which indicates effective treatment and helps prevent the accumulation of toxins in the body.
B: Significant increase in appetite and food intake.
While improved liver function may enhance appetite, lactulose primarily targets ammonia levels and bowel movement regularity rather than directly stimulating appetite or food intake in patients with hepatic encephalopathy.
C: Absence of nausea and vomiting.
Lactulose does not directly address nausea and vomiting, which can occur due to various factors in hepatic encephalopathy. The primary goal of lactulose is to manage ammonia levels and promote bowel regularity, not to eliminate gastrointestinal symptoms.
D: Absence of blood or mucus in stool.
Lactulose treatment focuses on reducing ammonia through soft bowel movements, not specifically on the presence or absence of blood or mucus in the stool. While blood or mucus may indicate other issues, they are not the primary concern with lactulose therapy in this context.
Lactulose is a non-absorbable disaccharide that helps reduce ammonia levels by promoting the excretion of ammonia through the stool. The desired outcome of administering lactulose in a patient with hepatic encephalopathy is to achieve two to three soft bowel movements daily, which indicates effective treatment and helps prevent the accumulation of toxins in the body.
B: Significant increase in appetite and food intake.
While improved liver function may enhance appetite, lactulose primarily targets ammonia levels and bowel movement regularity rather than directly stimulating appetite or food intake in patients with hepatic encephalopathy.
C: Absence of nausea and vomiting.
Lactulose does not directly address nausea and vomiting, which can occur due to various factors in hepatic encephalopathy. The primary goal of lactulose is to manage ammonia levels and promote bowel regularity, not to eliminate gastrointestinal symptoms.
D: Absence of blood or mucus in stool.
Lactulose treatment focuses on reducing ammonia through soft bowel movements, not specifically on the presence or absence of blood or mucus in the stool. While blood or mucus may indicate other issues, they are not the primary concern with lactulose therapy in this context.